Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Daratumumab practical considerations in MM

Torben Plesner • 16 May 2019
COMy 2019
Multiple Myeloma Daratumumab Dexamethasone Lenalidomide

Torben Plesner, MD, University of Southern Denmark, Odense, Denmark, shares practical considerations when using anti-CD38 antibodies, gained from his long experience of treating multiple myeloma with daratumumab. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Torben Plesner

4:43
Mechanistic insights into the resistance to anti-CD38 therapy
Torben Plesner • 14 Sep 2019
2:08
Novel drug delivery method to prevent daratumumab infusion-related reactions in MM
Torben Plesner • 19 Jul 2018
3:10
The challenges of treating plasma cell leukemia
Torben Plesner • 4 May 2018
1:43
Managing plasma cell leukemia: Pls, IMiDs, alkylating agents and antibodies
Torben Plesner • 4 May 2018

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals